Low muscle mass is associated with a higher risk of all–cause and cardiovascular disease–specific mortality in cancer survivors

• Published in: Nutrition (Burbank, Los Angeles County, Calif.) Vol. 107; p. 111934
• Main Authors: Zhang, Dongyu, Spiropoulos, Kori A., Wijayabahu, Akemi, Christou, Demetra D., Karanth, Shama D., Anton, Stephen D., Leeuwenburgh, Christiaan, Liang, Muxuan, Wheeler, Meghann, Yang, Danting, Livingstone, Aduse-Poku, Mankowski, Robert T., Cheng, Ting-Yuan David, Zhang, Hanchao, Siegel, Erin M., Penedo, Frank J., Licht, Jonathan D., Braithwaite, Dejana
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2023; Elsevier Limited
• Subjects: Adult; Body height; Cancer; Cancer Survivors; Cancer survivorship; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - diagnosis; Death; Diagnosis; Energy consumption; Epidemiology; Female; Geriatric oncology; Heart diseases; Humans; Low muscle mass; Male; Mortality; Muscles; Neoplasms - complications; Nutrition; Nutrition Surveys; Older people; Prognosis; Risk; Risk Factors; Statistical analysis; Statistical models; Survival; Womens health; United States > US; Low muscle mass; Nutrition; Epidemiology; Geriatric oncology; Cancer survivorship
• ISSN: 0899-9007; 1873-1244
• DOI: 10.1016/j.nut.2022.111934

•We conducted survival analysis for cancer survivors and their cancer-free counterparts by muscle mass.•Cancer survivors with low muscle mass are more likely to die or have fatal cardiovascular events.•Compared with their cancer-free counterparts, the effects of low muscle mass on mortality are stronger in cancer survivors. Individuals with prior cancer diagnosis are more likely to have low muscle mass (LMM) than their cancer-free counterparts. Understanding the effects of LMM on the prognosis of cancer survivors can be clinically important. The aim of this study was to investigate whether risks for all-cause and cardiovascular disease (CVD)–specific mortality differ by status of LMM in cancer survivors and a matched cohort without cancer history. We used cohort data from the 1999–2006 and 2011–2014 National Health and Nutrition Examination Survey. Participants included 946 adults surviving for ≥1 since cancer diagnosis and a matched cohort (by age, sex, and race) without cancer history (N = 1857). LMM was defined by appendicular lean mass and body height (men <7.26 kg/m2, women <5.45 kg/m2). Death was ascertained via the National Death Index and cause of death was assessed via International Classification of Diseases, Tenth Revision. Multivariable Cox proportional hazards models were used to estimate adjusted hazard ratio (aHR) and 95% confidence interval (CI) of LMM. The mean age of cancer survivors and matched cohort was 60.6 y (SD 15) and 60.2 y (SD 14.9), respectively. The median follow-up was 10.5 y for survivors and 10.9 y for matched cohort. Overall, 22.2% of cancer survivors and 19.7% of the matched cohort had LMM, respectively. In all, 321 survivors (33.9%) and 495 participants (26.7%) in the matched cohort died during follow-up. CVD-specific deaths were identified in 58 survivors (6.1%) and 122 participants in the matched cohort (6.6%). The multivariable Cox model suggested that LMM was positively associated with all-cause (aHR, 1.73; 95% CI, 1.31–2.29) and CVD-specific (aHR, 2.13; 95% CI, 1.14–4.00) mortality in cancer survivors. The associations between LMM and risk for all-cause (aHR, 1.24; 95% CI, 0.98–1.56) and CVD-specific (aHR, 1.21; 95% CI, 0.75–1.93) mortality were not statistically significant in the matched cohort. Cancer survivors with LMM have an increased risk for all-cause and CVD-specific mortality. This increase appears to be larger than that in counterparts without cancer history.